THE US Food and Drug Administration has approved a new oral antiviral flu medication called Xofluza (baloxavir marboxil).
The product was developed by Japanese firm Shionogi Co and will be marketed in the US by Genentech, a member of the Roche Group of companies.
Xofluza is indicated for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of age and older.
The above article was sent to subscribers in Pharmacy Daily's issue from 29 Oct 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Oct 18
